Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Nephrology  |  Oncology  |  Family Medicine  |  Urology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Bladder Cancer Clinical Trials

A listing of Bladder Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (32) clinical trials

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.

Phase

Evaluation of NanoDoce in Participants With Urothelial Carcinoma

In this clinical trial, subjects with high-risk non-muscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancer (MIBC), will receive NanoDoce. Subjects will be stratified into two treatment groups, Group 1 (NMIBC) and Group 2 (MIBC). All subjects will receive NanoDoce injected into the index tumor resection site on the ...

Phase

Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder

OUTLINE: This is a multi-center study. The phase Ib study will evaluate the safety of combining durvalumab with RT followed by adjuvant durvalumab. The phase II study will estimate the Progression Free Survival (PFS) and Disease Control Rate (DCR) with durvalumab plus RT followed by single agent durvalumab for patients ...

Phase

Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment na ve Advanced or Metastatic BTC

In phase 1B part, patients will receive Varlitinib plus Gemcitabine and Cisplatin, and follow a modified 3+3+3 study dose escalation scheme starting from Varlitinib 200 mg BID. The primary objective of the phase 1B part is to determine the MTD of Varlitinib when given in combination with Gemcitabine and Cisplatin, ...

Phase

Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder cancer is the seventh most common cancer in the UK and ninth most common cancer worldwide. New strategies for treating this disease are urgently required to reduce recurrence and progression rates. Pembrolizumab is a type of immunotherapy drug that has been approved for use in certain types of melanoma ...

Phase

A First-in-Human Study of alpha1H in Patients With Non-muscle Invasive Bladder Cancer

Protein-lipid complexes represent a new type of tumouricidal biologicals, with broad effects against cancers of different origins. The investigational product alpha1H is a synthetic peptide, corresponding to the alpha1 domain of -lactalbumin, in complex with oleic acid. Alpha1H is a further development product of HAMLET, a complex between human alpha-lactalbumin ...

Phase

Intervention of Bladder Cancer by CAR-T

This is a Phase I/II and multicenter study designed to evaluate the efficacy and safety of 4SCAR-T cells in participants with locally advanced or metastatic urothelial bladder cancer (UBC) who have no further treatment available.

Phase

Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms

By enrolling patients with unresectable Urinary Bladder Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Urinary Bladder Neoplasms.

Phase

A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors

Heparinized peripheral blood was obtained from participants over a 2-week period. PBMCs were separated by Ficoll-Hypaque gradient centrifugation, suspended in X-VIVO 15 serum-free medium, and culture with 1000 U/ml rhIFN-for the first 24 h, followed by stimulation with 100 ng/ml OKT3 , 1000 U/ml rhIL-2 and 100 U/ml IL-1 to ...

Phase

Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms

By enrolling patients with unresectable Gallbladder Neoplasms adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of percutaneous IRE for unresectable Gallbladder Neoplasms.

Phase